Keensight Capital to buy Symeres from Gilde Healthcare

Gilde's exit comes four years after it invested in the company in 2017. Partner Rafael Natanek said in a statement that the GP played an active role in the company's international expansion by participating in the merger of Mercachem with Syncom in 2017 and subsequent acquisitions of Alcami Weert and Admescope.

Keensight Capital will own a controlling stake in the company alongside its management and will support the company's organic growth and bolt-on strategy. Co-founder and CEO Eelco Ebbers said in a statement that the company planned to further expand its range of drug discovery and development services. In 2021, the group expects to reach over €70m in sales.

Keensight is currently deploying equity from Keensight Capital V, which held a final close in March 2019 on €1bn. 

Company
Founded in 1987 and based in Nijmegen, Symeres is a provider of R&D services from preclinical drug discovery to Phase-I and -II clinical stage drug development and manufacturing to pharmaceutical and biotechnology companies around the globe.

The company employs 500 people across the Netherlands, the Czech Republic, Finland and Sweden, along with a business development office in the US.

People
Keensight Capital - Amit Karna (partner).
Gilde Healthcare - Rafael Natanek (partner).
Symeres - Eelco Ebbers (co-founder, CEO).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Buyouts
• Benelux
• Healthcare
• Exits
• Netherlands
• Secondary buyout
• healthcare
• Keensight Capital
• Gilde Buy Out Partners